Back to Clinical Trials

Clinical Trials: Gastroenterology


Source: Valeant Pharmaceuticals International, Inc.
To establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately active ulcerative colitis after 6 weeks of therapy. Read More
Last Updated: 20 Dec 2009
Source: Valeant Pharmaceuticals International, Inc.
The objective of the study is to evaluate the long-term safety and tolerability of treatment with balsalazide disodium tablets in subjects who are in remission from ulcerative colitis or who have mildly to moderately active UC. Read More
Last Updated: 20 Dec 2009
Source: Prometheus Laboratories
An observational study to evaluate LOTRONEX® in women with severe IBS-D in the current clinical practice setting. Read More
Last Updated: 31 Mar 2013
Source: Millennium Pharmaceuticals, Inc.
This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission. Read More
Last Updated: 18 Jun 2014
Source: Exact Sciences Corporation
The primary objective is to determine the sensitivity and specificity of the Exact Colorectal Cancer (CRC) screening test for colorectal cancer, using colonoscopy as the reference method. Lesions will be confirmed as malignant by histopathologic examination. The secondary objective is to compare the performance of the Exact CRC screening test to a commercially available FIT assay, both with respect to cancer and advanced adenoma. Lesions will be confirmed ... Read More
Last Updated: 30 Nov 2015
Source: Abbott
The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication) Read More
Last Updated: 22 Sep 2007
Source: Shire
To evaluate the percentage of subjects with clinical recurrence of UC at 6 months using MMX mesalamine once daily. Read More
Last Updated: 18 Oct 2011
Source: Millennium Pharmaceuticals, Inc.
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks. Read More
Last Updated: 18 Jun 2014
Source: Otsuka Pharmaceutical Development & Commercialization, Inc.
The purpose of this study is to evaluate the safety and efficacy of the drug OPC-6535 compared to a placebo in patients with active Ulcerative Colitis. Depending on their response, participants will be offered the investigational medication for up to one year after the study's completion at select sites. Read More
Last Updated: 08 May 2012
Source: Biogen
The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn's Disease. Read More
Last Updated: 13 Jun 2016
Source: Abbott
Purpose of the study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease when compared to placebo (an inactive substance) Read More
Last Updated: 10 Aug 2006
Source: Altheus Therapeutics, Inc.
This double-blind, randomized, comparator-controlled Phase II study is designed to establish the safety and efficacy of Zoenasa Rectal Gel compared to mesalamine enema in subjects with left-sided ulcerative colitis, as measured by the modified ulcerative colitis disease activity index (UCDAI), over 6 weeks of treatment. In this study, two cohorts of subjects will receive either Zoenasa-1:4 (1.0g NAC; 4.0g 5-ASA) investigational drug enema therapy or ... Read More
Last Updated: 06 Jan 2014
Source: Valeant Pharmaceuticals International, Inc.
To evaluate the long-term safety and tolerability of mesalamine pellets (MP)in patients with ulcerative colitis currently in remission. Read More
Last Updated: 12 Jun 2011
Source: Valeant Pharmaceuticals International, Inc.
This is placebo-controlled study of three rifaximin doses in patients with DIBS. Subjects will be randomized to receive daily doses of placebo BID, rifaximin 275 mg BID, rifaximin 550 mg BID, or 1100 mg BID for 14 days. These four groups will subsequently receive an additional two weeks of placebo for a total of 4 weeks of treatment. A fifth group of subjects will receive rifaximin 550 mg BID for a period of 28 days. Subjects who successfully respond to ... Read More
Last Updated: 20 Dec 2009
Source: Millennium Pharmaceuticals, Inc.
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks. Read More
Last Updated: 18 Jun 2014
Source: Synta Pharmaceuticals Corp.
STA-5326 is an experimental drug that has been shown to block the release of interleukin-12 from peripheral blood mononuclear cells. Given this activity on the immune system, STA-5326 mesylate is a potential treatment for various autoimmune diseases, such as Crohn's disease, that are mediated by the inappropriate expression of Th1 cytokines. This study is evaluating the use of STA-5326 mesylate in patients with moderate to severe, active Crohn's disease. ... Read More
Last Updated: 02 Dec 2008
Source: Celgene Corporation
A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults with Moderately Severe Crohn's Disease Read More
Last Updated: 29 Nov 2016
Source: Shire
The purpose of this study is to determine whether SPD476 is effective in reducing recurrence of diverticulitis. Read More
Last Updated: 05 Jun 2014
Source: Sandoz
An Investigator-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Establish Therapeutic Equivalence of 1000 mg Mesalamine Rectal Suppositories and Canasa® Rectal Suppositories (1000 mg Mesalamine, USP) in the Treatment of Mild to Moderate Ulcerative Proctitis will be conducted in 533 patient with a estimated duration of 18months. Read More
Last Updated: 14 Jul 2015
Source: Epigenomics, Inc
The study aims to show non-inferiority in the clinical performance of the investigational assay, Epi proColon, to FIT using matched blood and stool specimens from screening-guideline eligible subjects. Read More
Last Updated: 02 Aug 2015
Page 1 of 50